Clinical trials

The objective of clinical trials is to improve patient care and treatment at all stages of disease. They assess the efficacy and safety of new treatments before these are offered to all suitable patients.

These new treatments may be new drugs, combinations of drugs, new ways of administering them or new treatment techniques (surgery, radiotherapy). Clinical studies may be initiated by the pharmaceutical industry, groups of cooperating centres or Gustave Roussy itself.

Team members

• Head of the genomic platform: Nathalie DROIN, PhD
  (nathalie.droin@gustaveroussy.fr)
• Marie BRECKLER, Technician
• Betty LEITE, Technician
• Audrey NAIMO, Technician
• Maëla FRANCILLETTE, engineer
• Béatrice FIET, assistant manager

Collective email address: GD-UGF@gustaveroussy.fr

Equipment

• 2 Bioanalyzer 2100 (Agilent)
• 1 FragmentAnalyzer (Agilent)
• 1 S220 Ultrasonicator (Covaris)
• 1 E220 Ultrasonicator (Covaris)

• 1 Robot Bravo (Agilent)
• 1 Robot SpriWorks (Beckman)

• 2 Chromium™ Controller (10X Genomics)
• 1 Tapestri (Mission Bio)

1 NovaSeq6000 (Illumina)

• 1 MiSeq (Illumina)
• 1 MiniSeq (Illumina)
• 1 PromethION 48 (Oxford Nanopore)

Gustave Roussy's US AMMICa Genomics Platform (INSERM US23 / CNRS UMS3655) aims to characterize cancers and experimental models using innovative genomic approaches.

Imaging and Cytometry Platform

• Cytometry & Mass imaging
• Microscopy
• Clinical Transfer Imaging

Gustave Roussy Transfert team members​

• CEO
  Fabrice Barlesi
• Executive director
  Christophe Javaud 
• Business developers
  Jérôme Gaborit
  Pierre Gandille
• Patent engineer / Responsable propriété intellectuelle
  Frédérique Le Bellego
• Patent engineer
  Sacha Cataldo
• Chargée de mission Accords et licences / Responsable gestion financière
  Daphné Descarpentries

From Innovation to the Patient

In 2000, Gustave Roussy established its subsidiary devoted to development: Gustave Roussy Transfert.
The Institute is the majority shareholder in this limited liability company with a capital of 200,200 euros, which is intended to :